Avapritinib also exerts activity against platelet-derived growth factor receptor alfa (PDGFRA) mutants, and was approved by the FDA in 2020 for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring PDGFRA exon 18 mutations [24,25]. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.